An interventional study of Tenosynovial biopsy in Transthyretin Amyloidosis, Transthyretin Cardiac Amyloidosis and Wild-Type Transthyretin-Related (ATTR)Amyloidosis, sponsored by Steen Hvitfeldt Poulsen. Completed at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.
Sponsored by Steen Hvitfeldt Poulsen · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark — 6 open to participants now, 7 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · Denmark.
Among the 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark, this one is one of 2 that started in 2020, is the only one with no phase, and was the 5th registered.
82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.
Browse Amyloidosis, Hereditary, Transthyretin-Related studies →6 of the 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark are open now. Recruiting first, the newest first:
Bayer · Sites in Denmark, Austria, Belgium and 14 more countries
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in Denmark, United States, Argentina and 21 more countries
Ages 18–75
Steen Hvitfeldt Poulsen · Sites in Denmark
Ages 18+ · Healthy volunteers
Intellia Therapeutics · Sites in Denmark, United States, Argentina and 23 more countries
Ages 18–90
Alnylam Pharmaceuticals · Sites in Denmark, United States, Brazil and 9 more countries
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2020.
This study's enrollment of 109 is above the median of 80 across 36 interventional studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.
Median enrollment 632 across the 7 interventional studies, 1,750 across the 4 observational. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 6 most frequent:
Steen Hvitfeldt Poulsen is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Steen Hvitfeldt Poulsen has 2 studies filed under Amyloidosis, Hereditary, Transthyretin-Related — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients above the age of 60 will be recruited at their carpal tunnel release surgery. Biopsies will be taken from the wrist and examined for the presence of amyloid protein. A amyloid-positive biopsy will refer the patients for cardiac examination including blod- and urine samples examined for transthyretin.
If the result of the cardiac examination is suspected cardiac amyloidosis, the patient will be referred for a diagnostic TC99-DPD scintigraphy. If the scintigraphy is positive, the patient will be referred for right heart catherization (RHC) and an exercise test.
Myocardial biopsies will be taken at the RHC and examined with electron microscopy and high resolution respirometry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: Tenosynovial biopsy
Tenosynovial biopsy taken from the wrist at the carpal tunnel release surgery.
Prevalence of wild-type transthyretin cardiac amyloidosis in patients undergoing surgery for idiopathic Carpal Tunnel Syndrome Surgery where biopsies from transverse carpal ligament stain positive for amyloid.
We will examine the amyloid deposits prevalence in biopsies from the Carpal Tunnel and ATTRwt prevalence in an aged and predominantly male population operated for idiopathic Carpal Tunnel Syndrom. Diagnosis of wild-type cardiac amyloidosis will be determined by TC99-DPD scintigraphy, endomyocardial biopsy, or both. Biopsies will be examined using Congo Red staining and fluorescent light
Time frame: Through study completion, 6 years.
Levels of transthyretin in blood and urine from patients with suspected wild-type transthyretin cardiac amyloidosis
We will investigate the plasma and urine levels of different forms of TTR (total TTR, misTTR, and fragTTR) in patients with amyloid deposits in the transverse carpal ligament, patients subsequently diagnosed with ATTRwt-CM and in patients with already diagnosed ATTRwt matched age and gender. We will investigate whether the levels of TTR is higher among ligament amyloid positive patients that are subsequently diagnosed ATTRwt-CM as compared to those without ATTR-CM.
Time frame: Has been added after study start, will run through study completion, 3 years.
Comparing patients diagnosed with wild-type transthyretin cardiac amyloidosis due to screening with age and gender matched clinically diagnosed ATTRwt patients.
Compare NAC-stage, NYHA-class, LVEF ect.
Time frame: Through study completion, 6 years.
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2020 to primary completion in May 2025, 61 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloidosis, Hereditary, Transthyretin-Related →
Steen Hvitfeldt Poulsen